ClarivateTM Analytics released the 2021 update of its Journal Citation Reports©, including the much anticipated 2020 impact factor. EASL’s flagship monthly journal, the Journal of Hepatology, achieved unprecedented results with a 2020…

For Immediate Release Media Release Treatment advances for Non-Alcoholic Fatty Liver Disease (NAFLD) announced at ILC 2021 New data released on trials involving RNAi therapeutics, antivirals and structurally engineered fatty acids to…

For Immediate Release Media Release Advances in new drugs to for curing Hepatitis B and Hepatitis D announced at ILC 2021 Thursday 24 June 2021 (Geneva, Switzerland)-- Leading hepatology researchers announced important…

For Immediate Release Media Release ILC 2021 opens with focus on impact of COVID-19 on global liver disease New data demonstrates that chronic liver disease increased the odds of COVID-19 death by 80% and Pfizer-BioNTech COVID-19…

About EASL and the A-TANGO Consortium The A-TANGO Consortium, a five-year project, consists of 14 institutions across eight countries in Europe. It aims to perform Phase II clinical studies of an innovative…

At EASL, we are pleased to support the relaunch of the international reporting registry COVID-Hep 2.0. Accordingly, EASL encourages healthcare professionals to share the registry among its networks. Every individual and centre…